2004 - Present Consultant, Palatin Technologies, Inc., Cranbury, New Jersey. Clinical FSD Phase 2a and 2b trial to evaluate PT-141.
2004 - Present Steering Committee, Outcomes Sub-Committee, Sanofi-Aventis, New York, New York. BPH Registry.
2003 - Present Independent Investigator-initiated research on the relationship of masturbation to retarded ejaculation, New York, New York.
2005 Principal Investigator, Pfizer Inc., New York, New York. Clinical PE Extension study, using UK-3.
2004 - 2005 Principal Investigator, Pfizer Inc., New York, New York. Clinical PE Phase 2b trial, study, using UK-3.
2004 - 2005 Principal Investigator, Pfizer Inc., New York, New York. Clinical ED Phase 2 trial, study, using UK-3.
2004 - 2005 Principal Investigator, Alza Corporation, Mountain View, California. Clinical PE trial, study.
2001 - 2003 Sub-Investigator, Bayer Incorporated Phase II clinical trial. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Fixed Dose, Parallel Group, 3-Month Comparison Study to Investigate the Efficacy and Safety of the Phosphodiesterase Type V Inhibitor in Males with Erectile Dysfunction following Radical Prostatectomy. (PI - R. Shabsigh)
2001 - 2003 Sub-Investigator, Lilly/ICOS LLC Phase II clinical trial. A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of IC351 Administered On Demand; to Patients with Erectile Dysfunction. (PI - R. Shabsigh)
2001 - 2003 Sub-Investigator, TAP Pharmaceuticals clinical trial. Evaluation of the Clinical Status, Resource Utilization and Quality of Life of Erectile Dysfunction Patients via a Longitudinal Observational Outcomes Database. (PI - R. Shabsigh)
2001 - 2003 Sub-Investigator, Pfizer Inc. clinical trial. A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter, Flexible Dose Study to Evaluate the Efficacy and Safety of Viagra (Sildenafil Citrate) in Males with Erectile Dysfunction and Arterial Hypertension who are Taking Multiple Antihypertensive Treatment. (PI - R. Shabsigh)
2001 - 2002 Sub-Investigator, Nexmed (USA), Inc. Phase II clinical trial. Single-Blind, Parallel, Single Dose, Dose Escalating Study of the Safety of FEMPROX TM Cream in Female Subjects. (PI - R. Shabsigh)
2001 - 2002 Sub-Investigator, Pharmacia & Upjohn, Protocol No: 774-URO-0493-002. Preliminary efficacy study in pre-menopausal women with normal or impaired sexual function due to acquired arousal and/or orgasm disorder comparing PNU-142774E 1.0-mg to Placebo: double-blind with 8-week home treatment phase. (PI - Ridwan Shabsigh)
2000 - 2001 Sub-Investigator, Pentech Pharmaceuticals clinical trial. Phase III, Double-Blind Randomized, Placebo-Controlled, Parallel Group, Multicenter, Safety and Efficacy Study of Paroxetine HCI Capsules for the Treatment of Premature Ejaculation. (PI - R. Shabsigh)